Active, not recruitingPHASE2, PHASE3NCT04799275
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Studying Diffuse large B-cell lymphoma with chronic inflammation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Elizabeth A Brem, MDSWOG Cancer Research Network
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 422 enrolled
- Eligibility
- 75 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim, Anaheim, California, United States
- Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
- Kaiser Permanente-Bellflower, Bellflower, California, United States
- Tower Cancer Research Foundation, Beverly Hills, California, United States
- UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Kaiser Permanente-Fontana, Fontana, California, United States
- Kaiser Permanente South Bay, Harbor City, California, United States
- City of Hope Seacliff, Huntington Beach, California, United States
- City of Hope at Irvine Lennar, Irvine, California, United States
- Kaiser Permanente-Irvine, Irvine, California, United States
- City of Hope Antelope Valley, Lancaster, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04799275 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma with chronic inflammation
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT07538180Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCLSun Yat-sen University
- RECRUITINGNCT07070648Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PETFudan University
- RECRUITINGPHASE1, PHASE2NCT06829771Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06717347A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT06687772CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantWashington University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT06760039Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLSun Yat-sen University
- RECRUITINGPHASE2NCT06701357CR-CHOP+X in Previously Untreated DELRuijin Hospital
- RECRUITINGPHASE2NCT06664411Pola-ZR2P in Previously Untreated DLBCLNavy General Hospital, Beijing
See all trials for Diffuse large B-cell lymphoma with chronic inflammation →